Enanta Pharmaceuticals’ (ENTA) Market Outperform Rating Reaffirmed at JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a research report issued on Tuesday,Benzinga reports. They presently have a $21.00 target price on the biotechnology company’s stock, down from their prior target price of $22.00. JMP Securities’ target price indicates a potential upside of 133.07% from the stock’s previous close.

Several other analysts have also issued reports on ENTA. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

Enanta Pharmaceuticals Stock Down 3.5 %

Shares of NASDAQ:ENTA opened at $9.01 on Tuesday. The business’s 50 day moving average is $11.03 and its 200 day moving average is $12.36. Enanta Pharmaceuticals has a 12-month low of $8.51 and a 12-month high of $17.80. The stock has a market cap of $190.92 million, a price-to-earnings ratio of -1.65 and a beta of 0.56.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently bought and sold shares of ENTA. Barclays PLC increased its holdings in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 20,478 shares during the period. Geode Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 14,575 shares during the last quarter. Krensavage Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after purchasing an additional 246,736 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $360,000. Finally, State Street Corp increased its position in shares of Enanta Pharmaceuticals by 6.4% during the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after purchasing an additional 27,147 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.